Ionis Pharmaceuticals Inc Cash Flow Conversion Efficiency
Ionis Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has a cash flow conversion efficiency ratio of 1.288x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($565.53 Million) by net assets ($439.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ionis Pharmaceuticals Inc (1991–2025)
Cash flow conversion efficiency of Ionis Pharmaceuticals Inc from 1991 to 2025. This chart illustrates how Ionis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ionis Pharmaceuticals Inc (IONS) share price today for real-time trading data and today's change.
Ionis Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Ionis Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ionis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Ionis Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STORA ENSO R ADR 1
F:ENUS
|
0.025x |
|
Air Lease Corporation
NYSE:AL
|
0.049x |
|
Noble Corporation plc
NYSE:NE
|
0.060x |
|
ASHTEAD UNSP.ADR/4 LS-10
F:0LCA
|
N/A |
|
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
|
0.037x |
|
Dixon Technologies (India) Limited
NSE:DIXON
|
0.044x |
|
First Industrial Realty Trust Inc
NYSE:FR
|
0.040x |
|
Hainan Airlines Co Ltd A
SHG:600221
|
0.812x |
Annual Cash Flow Conversion Efficiency for Ionis Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Ionis Pharmaceuticals Inc from 1991 to 2025. Review Ionis Pharmaceuticals Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $489.09 Million | $-268.58 Million | -0.549x | +35.50% |
| 2024-12-31 | $588.35 Million | $-500.95 Million | -0.851x | -7.07% |
| 2023-12-31 | $386.69 Million | $-307.51 Million | -0.795x | -66.05% |
| 2022-12-31 | $572.89 Million | $-274.37 Million | -0.479x | -1300.46% |
| 2021-12-31 | $772.00 Million | $30.80 Million | 0.040x | -6.30% |
| 2020-12-31 | $843.00 Million | $35.89 Million | 0.043x | -79.25% |
| 2019-12-31 | $1.69 Billion | $345.72 Million | 0.205x | -59.60% |
| 2018-12-31 | $1.19 Billion | $602.89 Million | 0.508x | +22.10% |
| 2017-12-31 | $418.72 Million | $174.15 Million | 0.416x | +136.94% |
| 2016-12-31 | $99.56 Million | $-112.11 Million | -1.126x | -1170.20% |
| 2015-12-31 | $200.79 Million | $21.12 Million | 0.105x | +331.52% |
| 2014-12-31 | $257.78 Million | $6.29 Million | 0.024x | -85.47% |
| 2013-12-31 | $378.39 Million | $63.49 Million | 0.168x | +1534.74% |
| 2012-12-31 | $182.77 Million | $1.88 Million | 0.010x | +101.53% |
| 2011-12-31 | $171.43 Million | $-114.80 Million | -0.670x | -157.51% |
| 2010-12-31 | $244.54 Million | $-63.59 Million | -0.260x | +27.56% |
| 2009-12-31 | $302.06 Million | $-108.44 Million | -0.359x | -117.65% |
| 2008-12-31 | $104.25 Million | $212.03 Million | 2.034x | -42.28% |
| 2007-12-31 | $10.24 Million | $36.09 Million | 3.524x | +748.16% |
| 2006-12-31 | $97.90 Million | $-53.23 Million | -0.544x | +97.65% |
| 2005-12-31 | $2.67 Million | $-61.74 Million | -23.167x | -1742.37% |
| 2004-12-31 | $-72.13 Million | $-101.75 Million | 1.411x | +199.25% |
| 2003-12-31 | $67.18 Million | $-95.47 Million | -1.421x | -134.12% |
| 2002-12-31 | $155.48 Million | $-94.38 Million | -0.607x | -2099.26% |
| 2001-12-31 | $223.10 Million | $-6.16 Million | -0.028x | +92.10% |
| 2000-12-31 | $66.37 Million | $-23.19 Million | -0.349x | +99.42% |
| 1999-12-31 | $800.00K | $-48.40 Million | -60.500x | -832.28% |
| 1998-12-31 | $-4.20 Million | $-34.70 Million | 8.262x | +1499.71% |
| 1997-12-31 | $34.90 Million | $-20.60 Million | -0.590x | -62.60% |
| 1996-12-31 | $58.40 Million | $-21.20 Million | -0.363x | -82.47% |
| 1995-12-31 | $75.90 Million | $-15.10 Million | -0.199x | +39.79% |
| 1994-12-31 | $46.00 Million | $-15.20 Million | -0.330x | -26.34% |
| 1993-12-31 | $58.50 Million | $-15.30 Million | -0.262x | +46.34% |
| 1992-12-31 | $39.80 Million | $-19.40 Million | -0.487x | -1820.50% |
| 1991-12-31 | $59.10 Million | $-1.50 Million | -0.025x | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of heredita… Read more